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Rikke Buhl1* and Pyotr G. Platonov5
Abstract
Background: Atrial fibrillatory cycle length has been considered one of the indices of atrial electrical remodelling
during atrial fibrillation (AF), which can be assessed from surface ECG by computer-assisted calculation of atrial
fibrillatory rate (AFR). Horses have been suggested as a bona fide model for AF studies since horses too, develop
lone AF, however data on AF characteristics in horses are extremely sparse and non-invasive characterization of
AF complexity using surface ECG processing has not been reported.
Aim: The aim was to study characteristics of induced AF and its modification by flecainide.
Methods: The study group consisted on 3 horses with spontaneous persistent AF and 13 with pace-induced AF.
Seven horses were treated with saline (control) and eight with flecainide (2 mg/kg). ECGs were analysed using
spatiotemporal cancellation of QRST complexes and calculation of AFR from the residual atrial signal.
Results: At AF onset, AFR was 295 ± 52 fibrillations per minute (fpm) in the horses with induced AF treated with
flecainide, 269 ± 36 fpm in the control group (ns), and 364 ± 26 fpm in the horses with spontaneous persistent AF
(P < 0.05 compared to the control group). Flecainide caused a decrease in AFR in all animals and restored sinus
rhythm in the animals with induced AF. In the control animals, AFR increased from 269 ± 36 fpm to a plateau of
313 ± 14 fpm before decreasing to 288 ± 28 fpm during the last 10% of the AF episodes preceding spontaneous
conversion (P < 0.05).
Conclusion: AFR in horses with induced AF resembles AFR in humans with paroxysmal AF. Flecainide caused a
rapid decrease in AFR in all horses, further supporting the method to be a non-invasive technique to study the
effect of antiarrhythmic compounds.
Keywords: Antiarrhythmic drug, Atrial electrophysiology, Atrial fibrillation, Atrial fibrillatory rate, Animal model,
Equine, Flecainide, Horse, Programmed electrical stimulation
Background
Atrial fibrillation (AF) is a self-sustained arrhythmia that
progresses over time as a consequence of atrial remodel-
ling. Shortening of the atrial refractory period is consid-
ered to be the hallmark of the electrical remodelling,
and is closely linked to the atrial fibrillatory cycle length
or its reversed measure atrial fibrillatory rate (AFR)
expressed in fibrillations per minute (fpm) [1]. As a non-
invasive measurement of atrial remodelling, AFR has
been repeatedly validated against intracardiac recordings
[1, 2] and is expected to become a useful tool for assess-
ment of AF treatment strategies.
Recently, the horse has been proposed as a bona fide
model for AF. [3, 4] Like humans, horses develop AF both
with and without underlying cardiac diseases, which is be-
lieved to be a consequence of their large hearts and high
vagal tone. [5] In addition to the naturally occurring cases,
AF can be electrically induced in horses, allowing studies
of AF remodelling and treatment regimes.
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In clinical medicine, flecainide is a commonly used
drug to restore sinus rhythm in patients with recent-
onset AF. [6] There is an ongoing debate over the effect-
iveness and safety of flecainide as an antiarrhythmic
drug in horses, as the literature shows conflicting results.
A study by Ohmura et al. [7] describes flecainide to be
safe and efficient in restoring sinus rhythm in an experi-
mental setting, whereas a Belgian group reported disap-
pointing efficacy [8] and fatal side effects. [9] AFR has
been reported to decrease after flecainide treatment [3],
but whether non-invasive AFR assessment is suitable for
monitoring drug effects in horses (based on the process-
ing of surface electrocardiogram (ECG) recordings) is
yet to be studied.
Methods
The aim of this study was to assess AFR behaviour in
horses with atrial fibrillation and to study the effects of
flecainide on AFR using time-frequency analysis applied
to Holter ECGs.
ECGs from 13 Standardbred horses were collected. All
horses were electrically stimulated into AF using pro-
grammed electrical stimulation from a multipolar cath-
eter placed in the right atrium through the jugular vein.
After AF induction the horses were either treated with
saline (control group) or flecainide (flecainide group).
Continuous modified base-apex ECG was recorded dur-
ing the entire duration of the experiments. [3] The con-
trol group consisted of four mares and three geldings
(mean age 9.1 years, range 4–14; mean bodyweight
(BW) 497 kg, range 454–555). The flecainide group con-
sisted of five mares and two geldings (mean age 7.4 years,
range 4–16; mean BW 474 kg, range 390–552). One
horse received both saline and flecainide with a 6-day
wash-out period in between.
Following AF induction, a minimum of 15 min con-
tinuous AF was required before initiation of treatment
with either Flecainide (Tambocor, Meda AS, Allerød,
DK; n = 7) or isotonic saline (n = 7). Flecainide (2 mg/kg)
or saline were infused intravenously (IV) over a period
of 10 min. Five horses received three additional IV saline
injections (0.0125 ml/kg/min) 20 min apart. After infu-
sion the horses were monitored at rest until either drug
induced or spontaneous cardioversion occurred. In order
to minimize the risk of untimely spontaneous cardiover-
sion in horses scheduled for saline infusion, they were
required to have an AF episode of at least 1-h duration
to be included in the study.
Additionally, three horses with spontaneous AF docu-
mented with long-term continuous ECG registration
were included in the study (two Standardbreds, one
Warmblood), one mare and two geldings (mean age
8 years, range 7–10; mean BW 514 kg, range 464–548).
Horse A had successfully been treated for AF with
Quinidine Sulfate twice within recent years. The AF
episode included in this paper had lasted more than
3 weeks prior to flecainide treatment as described above.
The AF duration in horse B was also known to be over
3 weeks, whereas it was only possible to determine that
the AF duration in horse C was a minimum of 12 h, as
AF was an incidental finding and the horse was brought
straight to the clinic. There were no records of previous
AF episodes for horse B or C and no flecainide treat-
ment were attempted.
ECG recordings and signal processing
ECGs were recorded as a modified base-apex ECG. All re-
cordings for the induced horses included AF onset, saline
or flecainide infusion and termination of AF, while the
spontaneous persistent horses had minimum of 60 min
ECG recorded and analysed. All ECG recordings were
manually reviewed for quality assessment and the pres-
ence of AF in the Televet system (Kruuse, Langeskov, DK)
or Labchart software (LabChart 7 Pro, ADInstruments,
Oxford, UK). ECG analysis including QRST cancellation
and AFR calculation was performed using the Cardiolund
AFR Tracker software (cardiolund.com). [10] AFR values
where less than 10% of the signal could be used for auto-
mated analysis were discarded as missing values.
Statistical analysis
Data are presented as mean ± SD or mean ± SEM as ap-
propriate. To account for different AF duration when
studying AFR behaviour in the control horses, the me-
dian of the AFR values in the 10th, 45-55th and 90-
100th percentiles of AF duration in the individual horses
were calculated, and a Friedman’s one-way ANOVA was
performed, followed by Dunnett’s post hoc test. AFR
values were compared between groups using a Mann-
Whitney unpaired t-test, while a comparison of AFR
values before and after treatment was performed using
Wilcoxon matched pairs t-test where the mean of the
last 10 min prior to treatment was compared to the last
AFR value before cardioversion (flecainide group) or
mean of the following 10 min after injection start (con-
trol group). The threshold for statistical significance was
P < 0.05 throughout the study.
Results
The quality of the ECG recordings was generally good
and few segments (5.3%) of the ECGs were discarded
due to excessive levels of noise.
For the AF-induced horses, the mean AF duration in
the control group was 205 min (range 152–273) and
26 min (range 16–36) in the flecainide group.
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AFR dynamics in control horses during induced AF
AFR at initiation of AF was 269 ± 36 fpm (range 208–
317). AFR significantly increased in all horses from the
10th percentile (299 ± 10 fpm) to the 45-55th percentile
(313 ± 14 fpm; P < 0.05). Before spontaneous cardiover-
sion, AFR significantly decreased again at the 90-100th
percentile (302 ± 19 fpm; P < 0.05). Table 1 describes
the AFR and time at the different stages. The difference
between percentiles suggests a plateau or “steady state”
during which AFR was stable. Studying the individual
trends, the time to the plateau was 40 to 70 min in six
of the horses, while AFR in one horse continued to in-
crease for 140 min. The average time to plateau was 68
± 33 min, as illustrated in Fig. 1. All horses showed a
decrease in AFR during the last 30 ± 17 min prior to
spontaneous cardioversion.
The effect of flecainide on AFR during induced AF
At AF onset, AFR was 295 ± 52 fpm in the flecainide
group, which was non-significant compared to the con-
trol group (P > 0.05). Flecainide restored sinus rhythm in
all horses with induced AF. The duration of AF episodes
before treatment was on average 22 ± 5 min, and time to
cardioversion after flecainide infusion started was 4.3 ±
2.5 min. AFR decreased immediately after the initiation
of flecainide infusion (P < 0.05). In contrast, AFR in the
control group remained unchanged after saline infusion
(P > 0.05). Figure 2 illustrates the behaviour of AFR after
infusion with flecainide (2a) and saline (2b).
AFR in horses with spontaneous persistent AF
The horses with spontaneous persistent AF presented
with a significantly higher AFR compared to the horses
with electrically induced AF (P < 0.05; mean of the first
AFR value recorded 364 ± 26) and remained stable in the
absence of drug intervention (Fig. 3a). Sinus rhythm was
not restored in response to flecainide administration in
horse A, despite a decrease in AFR of more than 100 fpm
10 min after infusion (Fig. 3b).
Discussion
Main findings
In the present study, we found that AFR in horses
closely resembles AFR in humans, both in terms of rate,
behaviour over time, and response to drug injection. We
found an AFR range of 250–350 fpm in seven horses
with induced AF, which is well correlated with clinical
observations where patients with induced AF had a fre-
quency of 336 ± 78 beats/min, [2] and patients with par-
oxysmal AF reached a rate of 326 ± 39 fpm 3 h after
onset. [11] Two independent clinical studies have sug-
gested cut-off values of less than 350 fpm [12] and
355 fpm [13] for predicting spontaneous cardioversion.
As all AF-induced horses receiving saline in this study,
had AFR below this threshold and cardioverted spontan-
eously, it seems that these cut-off values may also apply
to horses. Atrial remodelling will advance as AF acceler-
ates as a consequence of AF itself. [14] As AFR can be
used to assess atrial remodelling, it is reasonable to
expect that AFR will evolve with increased AF duration.
In agreement, we found the three horses with spontan-
eous persistent AF to have a mean of the first AFR value
recorded at rest of 364 ± 26, which is considerably higher
Table 1 AFR behaviour in the control horses
AFR (fpm) Time (minutes)
Initiation of AF 269 ± 36† 1
0-10th percentile 299 ± 10† 21 ± 4.9
45-55th percentile 313 ± 14 92 ± 22–112 ± 27
90-100th percentile 302 ± 19† 183 ± 44–204 ± 49
Last value prior to termination 288 ± 28† 205 ± 50
AFR (fpm) and time (minutes) described at initiation of AF, the first, middle
and last 10% of the AF episodes, and the last value before termination. All
values are presented as mean ± SD
†Differs significantly from the 45-55th percentiles (P < 0.05)
Fig. 1 AFR in control horses at AF onset (a) and before spontaneous cardioversion (b). a illustrates an increase in AFR in the first 70 min
before reaching a plateau. b illustrates the gradual decrease in AFR 30 min before restoration of sinus rhythm at time = 0. Values are
presented as mean ± SEM, n = 7
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than the short-term induced AF and also in agreement
with human AF studies, in which patients with AF epi-
sodes longer than 3 months had a frequency of 402 ± 78
beats/min. [2]
AFR dynamics in control horses
In the present study, we found an increase in AFR from
AF onset, and six out of seven horses had reached a
plateau after 70 min. Using similar methodology, Boll-
mann et al. [15] and Petrutiu et al. [16] reported time
to a plateau being 4–5 min in patients with short AF
episodes that lasted several minutes. Platonov et al. [11]
observed an increase in AFR during the first 3 to 4 h in
a study where one patient had 8.5 h of AF, and the
remaining three patients had AF episodes of more than
48 h. The mean AF duration in our control horses was
3.4 h, suggesting that time to reach a plateau may de-
pend on the duration of the AF episode, since both the
length of the episodes and AFR are likely to reflect the
degree of the atrial remodelling. This is further sup-
ported by the observations that no change in AFR was
found when the duration of AF episodes was less than
15 min. [15] This study also indicates that horses with
longer AF duration reached the plateau later. However,
it is important to note that AF was induced in these
horses, and that the sample size was rather small.
Before termination of AF, we observed a pronounced
decrease in AFR. As with the initial AFR increase, the
literature presents some inconsistencies on this matter –
Bollmann et al. [2] observed no changes in AFR towards
termination using a 10-s time frame, while Petrutiu et al.
[16] observed an abrupt decrease when AFR was studied
on a second-to-second basis. In contrast, Platonov and
colleagues [11] observed a gradual decrease 1 h before
spontaneous cardioversion in one patient, while Fujiki
[17] demonstrated a slowing of AFR 10 min prior to ter-
mination in patients that cardioverted in the morning. It
is most likely that the different observations were due to
different AF durations, suggesting that short-term AF
episodes terminate more quickly with little or no change
in AFR, while longer AF episodes have a gradual AFR
decrease before spontaneous termination.
The effect of flecainide on AFR
Flecainide is a class I antiarrhythmic drug that slows
down atrial fibrillatory process in horses [3, 8] and in
humans. [18] The present study showed a clear effect of
flecainide on AFR retrieved from surface ECGs, as AFR
Fig. 2 AFR 10 min before and after treatment was initiated (at time = 0). Data are presented as mean ± SEM. a represents the horses treated with
flecainide. Note the rapid change in AFR as a consequence of flecainide administration. b represents the horses treated with saline
Fig. 3 AFR in horses with spontaneous persistent AF. Data are presented as 10-min average. a illustrates a stable AFR without drug intervention
(n = 3) and b illustrates the attempt to terminate AF with flecainide (injection time = 0, n = 1). Note the significant decrease in AFR after flecainide
infusion, followed by an increase as the flecainide failed to restore sinus rhythm
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dropped immediately after infusion started. The same ef-
fect was seen when 18 patients with AF were treated with
oral flecainide, which resulted in a frequency drop of 30%.
[19] Patients with low frequency atrial fibrillation were
more likely to cardiovert spontaneously or in response to
treatment than patients with high frequency fibrillation.
[15] Our study shows that this may also apply to horses,
as flecainide terminated AF in the induced horses that had
a significantly slower rate than those with spontaneous
persistent AF. Flecainide reduced AFR by 100 fpm to a
level similar to the induced horses, yet this was not suffi-
cient, as AFR started to increase again before cardiover-
sion, leaving the horse in AF. Likewise, Bollmann et al.
[15] showed that AF frequency decreases in response to
flecainide treatment (P < 0.001) without restoring sinus
rhythm. Several other studies have investigated the effect
of a number of antiarrhythmic drugs, [20] all shown to re-
duce AFR. This supports AFR as a non-invasive method
of tracking the effect of antiarrhythmic compounds in
order to understand the effect on AF in humans and now
also in horses.
Conclusion
To our knowledge, this is the first analysis of the non-
invasive characterization of AF in horses. AFR values and
their evolution during induced AF in horses resemble
AFR dynamics in humans with paroxysmal AF, and horses
with spontaneous persistent AF demonstrate an increase
in AFR similar to patients with long-lasting AF. Flecainide
caused a rapid decrease in AFR, suggesting that AFR
measurement is a non-invasive method to monitor the ef-
fects of antiarrhythmic compounds in AF and supporting
the validity of the horse as a model for human AF.
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